While the controversy surrounding Vertex Pharma’s cystic fibrosis drug in the UK grows more intense, the US firm has announced that it is licensing back two gene editing compounds that can
As biosimilar competition to Herceptin ramps up, Roche is looking to bolster its position in HER2-positive breast cancer with a new indication for Kadcyla.
Ahead of the 2019 eyeforpharma Barcelona conference, we asked speaker and awards judge Heather Moses – head of medical affairs at Roche – what she is looking for in winning patient init
Roche and AC Immune have discontinued phase III trials of their Alzheimer’s disease drug crenezumab after an interim analysis indicated it would not hit its primary endpoint.
Three more big pharma R&D names have made the jump to biotech as Voyager Therapeutics, ImmunSYS and Immunocore announce they have appointed former execs from Roche, Novartis and AstraZe